Back to mobile site

Stifel Reiterates Buy Rating on Syndax Pharmaceuticals (SNDX)

June 15, 2026 9:32 AM EDT Send to a Friend
Stifel analyst Stephen Willey reiterated a Buy rating and $46.00 price target on Syndax Pharmaceuticals (NASDAQ: SNDX).The analyst commented, "The ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE

Member Login